User: Guest  Login
Title:

Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice.

Document type:
Journal Article
Author(s):
Talvard-Balland, Nana; Braun, Lukas M; Dixon, Karen O; Zwick, Melissa; Engel, Helena; Hartmann, Alina; Duquesne, Sandra; Penter, Livius; Andrieux, Geoffroy; Rindlisbacher, Lukas; Acerbis, Andrea; Ehmann, Jule; Köllerer, Christoph; Ansuinelli, Michela; Rettig, Andres; Moschallski, Kevin; Apostolova, Petya; Brummer, Tilman; Illert, Anna L; Schramm, Markus A; Cheng, Yurong; Köttgen, Anna; Duyster, Justus; Menssen, Hans D; Ritz, Jerome; Blazar, Bruce R; Boerries, Melanie; Schmitt-Gräff, Annette; Sar...     »
Abstract:
Leukemia relapse is a major cause of death after allogeneic hematopoietic cell transplantation (allo-HCT). We tested the potential of targeting T cell (Tc) immunoglobulin and mucin-containing molecule 3 (TIM-3) for improving graft-versus-leukemia (GVL) effects. We observed differential expression of TIM-3 ligands when hematopoietic stem cells overexpressed certain oncogenic-driver mutations. Anti-TIM-3 Ab treatment improved survival of mice bearing leukemia with oncogene-induced TIM-3 ligand exp...     »
Journal title abbreviation:
J Clin Invest
Year:
2024
Journal volume:
134
Journal issue:
16
Fulltext / DOI:
doi:10.1172/JCI177460
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/38916965
Print-ISSN:
0021-9738
TUM Institution:
Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie (Prof. Bassermann)
 BibTeX